Abstract 63P
Background
Eribulin, a novel anti-tubulin agent, is a preferred treatment for patients (pts) with metastatic breast cancer (mBC) who have been pretreated with anthracycline and/or taxane-based therapy. Preclinical data suggest a potential synergistic effect of eribulin and platinum. However, clinical data on the combination for mBC are lacking. We evaluated eribulin plus platinum in pts with mBC.
Methods
This multi-center, real-world cohort study included pts with pre-treated metastatic triple- negative breast cancer (TNBC) or endocrine-refractory hormone receptor (HR) -positive, HER2 -negative mBC who received eribulin plus carboplatin (ErCb). Eribulin (1.4 mg/m2) and carboplatin (target AUC=2) were administered intravenously on days 1 and 8 of 21-day cycles. Progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and adverse events (AEs) were evaluated.
Results
From March 2022 to August 2023, 19 pts with TNBC and 11 with HR+HER2- mBC were included. Of the 19 pts with TNBC, 8 had an initial diagnosis of HR+HER2- disease. All 30 pts were female, with a median (range) age of 46 (31–60) years and had received a median of 2 (1–6) prior lines of therapy. Visceral metastases were present in 22 pts (73.3%). Best overall response, ORR, DCR, and PFS are shown in the table. Median overall survival was not reached. After a median of 6 cycles (range, 2–8) of ErCb, the most common grade 3–4 AEs were neutropenia (40.0%), leukopenia (23.3%), febrile neutropenia (10.0%), and anemia (3.3%). No grade 3–4 non-hematological AEs were observed. Table: 63P
| Patients, n (%) | |||
| Response | All patients (N=30) | TNBC group (N=19) | HR+HER2- group (N=11) |
| Complete response | 0 | 0 | 0 |
| Partial response | 19 (63.3) | 12 (63.2) | 7 (63.6) |
| Stable disease | 7 (23.3) | 4 (21.1) | 3 (27.3) |
| Progressive disease | 4 (13.3) | 3 (15.8) | 1 (9.1) |
| ORR | 19 (63.3) | 12 (63.2) | 7 (63.6) |
| DCR | 26 (86.6) | 16 (84.2) | 10 (91.0) |
| Median PFS, months (95% CI) | 5.0 (4.0-6.0) | 5.0 (1.3-8.7) | 5.6 (3.0-8.1) |
Conclusions
In this cohort of pts with heavily pre-treated HER2- mBC, ErCb demonstrated promising efficacy and a manageable safety profile. Further studies exploring this combination in earlier lines of treatment for mBC are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract